Screener
Ocular Therapeutix OCUL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 400,000,000 and 400,000,000 shares authorized and 218,896,915 and 215,927,600 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 22 | 22 |
| Additional paid-in capital | 1,827,187 | 1,811,311 |
| Accumulated deficit | (1,245,635) | (1,157,023) |
| Total stockholders’ equity | 581,574 | 654,310 |
| Total liabilities and stockholders’ equity | $732,529 | $808,057 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's total equity?
- Ocular Therapeutix (OCUL) reported total equity of $581.57M in Q1 2026.
- How has Ocular Therapeutix's total equity changed year-over-year?
- Ocular Therapeutix's total equity increased by 118.7% year-over-year, from $265.93M to $581.57M.
- What is the long-term trend for Ocular Therapeutix's total equity?
- Over 5 years (2020 to 2025), Ocular Therapeutix's total equity has grown at a 53.8% compound annual growth rate (CAGR), from $76.1M to $654.31M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Ocular Therapeutix's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude